公开(公告)号：US20170027863A1

公开(公告)日：2017-02-02

申请号：US15207562

申请日：2016-07-12

申请人： LUPIN LIMITED

发明人： Ashish Ashokrao DESHMUKH ,  Pravin Meghrajji BHUTADA ,  Sajeev CHANDRAN ,  Shirishkumar KULKARNI

IPC分类号： A61K9/00 ,  A61K31/4545

CPC分类号： A61K9/0053 ,  A61K9/0004 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2072 ,  A61K9/2086 ,  A61K9/209 ,  A61K9/2846 ,  A61K9/2866 ,  A61K31/4545

摘要： The present invention relates to oral controlled release pharmaceutical compositions comprising Bepotastine. The oral controlled release pharmaceutical composition comprises Bepotastine or pharmaceutically acceptable salts thereof and at least one release controlling agent. The present invention also provides the use of oral controlled release pharmaceutical compositions of Bepotastine for the treatment of allergic rhinitis and for the treatment of pruritus caused by urticaria.

摘要翻译： 本发明涉及包含布替沙星的口服控释药物组合物。 口服释放药物组合物包含布替托汀或其药学上可接受的盐和至少一种释放控制剂。 本发明还提供了布替斯汀的口服控释药物组合物用于治疗过敏性鼻炎和治疗由荨麻疹引起的瘙痒的用途。

公开(公告)号：US20200375959A1

公开(公告)日：2020-12-03

申请号：US16868307

申请日：2020-05-06

申请人： Lupin Limited

发明人： Shirishkumar KULKARNI ,  Satish Kumar DALAL ,  Harshal Anil JAHAGIRDAR

IPC分类号： A61K31/437 ,  A61K9/10 ,  A61K9/20 ,  A61K47/32 ,  A61K47/10

摘要： A solid dispersion of rifaximin comprising rifaximin and pharmaceutically acceptable carrier. A pharmaceutical composition comprising the solid dispersion of rifaximin.

公开(公告)号：US20140221414A1

公开(公告)日：2014-08-07

申请号：US14151515

申请日：2014-01-09

申请人： LUPIN LIMITED

发明人： Shirishkumar KULKARNI ,  Satish Kumar DALAL ,  Harshal Anil JAHAGIRDAR

IPC分类号： A61K31/437

CPC分类号： A61K31/437 ,  A61K9/0043 ,  A61K9/0046 ,  A61K9/0056 ,  A61K9/10 ,  A61K9/2013 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/2086 ,  A61K47/10 ,  A61K47/32 ,  Y02A50/473

摘要： A solid dispersion of rifaximin comprising rifaximin and pharmaceutically acceptable carrier. A pharmaceutical composition comprising the solid dispersion of rifaximin.

摘要翻译： 利福昔明的固体分散体，其包含利福昔明和药学上可接受的载体。 包含利福昔明的固体分散体的药物组合物。

公开(公告)号：US20190076536A1

公开(公告)日：2019-03-14

申请号：US15943368

申请日：2018-04-02

申请人： LUPIN LIMITED

发明人： Harshal Anil JAHAGIRDAR ,  Rajesh KULKARNI ,  Shirishkumar KULKARNI

IPC分类号： A61K47/44 ,  A61K38/12 ,  A61K9/00 ,  A61K47/34 ,  A61K47/38 ,  A61K31/4402 ,  A61K31/197 ,  A61K31/785 ,  A61K31/196

摘要： A novel pharmaceutical composition, which comprises a therapeutically effective amount of active principle(s) or a pharmaceutically acceptable salt or enantiomer or polymorph thereof, optionally one or more release controlling agent(s) and pharmaceutical acceptable excipient(s) thereof, wherein the composition is formulated to increase the residence time of the said pharmaceutical composition and/or active principle(s) in the gastrointestinal tract. A novel pharmaceutical composition comprising at least two entities wherein one entity is an immediate release/fast release and the other is controlled release. A pharmaceutical composition comprising at least two entities wherein one entity is an immediate release/fast release and the other is bioadhesive. A pharmaceutical composition comprising: at least two entities wherein one entity is controlled release and the other is bioadhesive All the three compositions are formulated to increase the residence time of active principle(s) in the gastrointestinal tract. A multilayered composition with active in a layer which provides immediate release or controlled release of active principles and layer providing increased residence time in the GI tract.

公开(公告)号：US20150343070A1

公开(公告)日：2015-12-03

申请号：US14611578

申请日：2015-02-02

申请人： LUPIN LIMITED

发明人： Harshal Anil JAHAGIRDAR ,  Rajesh KULKARNI ,  Shirishkumar KULKARNI

IPC分类号： A61K47/44 ,  A61K38/12 ,  A61K31/196 ,  A61K47/32 ,  A61K31/197 ,  A61K31/4402 ,  A61K47/38 ,  A61K47/34 ,  A61K31/437 ,  A61K31/785

CPC分类号： A61K47/44 ,  A61K9/0065 ,  A61K9/0095 ,  A61K9/1611 ,  A61K9/1617 ,  A61K9/1623 ,  A61K9/1635 ,  A61K9/1641 ,  A61K9/1652 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/205 ,  A61K9/2054 ,  A61K9/2086 ,  A61K9/209 ,  A61K31/196 ,  A61K31/197 ,  A61K31/437 ,  A61K31/4402 ,  A61K31/606 ,  A61K31/635 ,  A61K31/655 ,  A61K31/785 ,  A61K38/12 ,  A61K47/32 ,  A61K47/34 ,  A61K47/38

摘要： A novel pharmaceutical composition, which comprises a therapeutically effective amount of active principle(s) or a pharmaceutically acceptable salt or enantiomer or polymorph thereof, optionally one or more release controlling agent(s) and pharmaceutical acceptable excipient(s) thereof, wherein the composition is formulated to increase the residence time of the said pharmaceutical composition and/or active principle(s) in the gastrointestinal tract. A novel pharmaceutical composition comprising at least two entities wherein one entity is an immediate release/fast release and the other is controlled release. A pharmaceutical composition comprising at least two entities wherein one entity is an immediate release/fast release and the other is bioadhesive. A pharmaceutical composition comprising: at least two entities wherein one entity is controlled release and the other is bioadhesive All the three compositions are formulated to increase the residence time of active principle(s) in the gastrointestinal tract. A multilayered composition with active in a layer which provides immediate release or controlled release of active principles and layer providing increased residence time in the GI tract.